Price reductions for liquid culture tests will accelerate access to improved TB diagnostics
SEATTLE, June 17 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company; NYSE: BDX), a leading global medical technology company, and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and accelerates the implementation of new diagnostic tools for poverty-related diseases, today announced a significant price reduction in the cost of liquid culture testing.
The agreement lowers the cost of BD MGIT(TM) reagents. BD's TB diagnostic technologies utilize liquid culture, a key "standard of care" TB testing protocol that provides results far faster than traditional, solid media culture. The liquid culture test, widely used in modern research settings, is particularly effective for stemming the spread of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in developing countries.
"By collaborating with such leading global health organizations as FIND, BD's Global Health initiative implements diagnostic programs that help strengthen healthcare infrastructures in developing countries," said Krista Thompson, Vice President and General Manager, Global Health, BD. "With an emphasis on accessibility, affordability and sustainability, BD provides on-the-ground technical assistance, training and products that maximize the capacity to diagnose TB, including drug-resistant strains, in nations where the disease is most prevalent."
The price reduction -- announced five months earlier than anticipated -- arises from a November 2007 agreement between BD and FIND. At that time, BD agreed to reduce already below-market prices upon the completion of 3.5 million tests, a milestone achieved this month. The lower prices will enable more tests to be administer
|SOURCE BD (Becton, Dickinson and Company)|
Copyright©2009 PR Newswire.
All rights reserved